Back to top
more

Revance Therapeutics (RVNC)

(Delayed Data from NSDQ)

$3.57 USD

3.57
1,789,023

-0.09 (-2.46%)

Updated Apr 24, 2024 04:00 PM ET

Pre-Market: $3.53 -0.04 (-1.12%) 9:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RVNC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Revance Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 254 341 225 437 290
Receivables 28 11 3 2 0
Notes Receivable 0 0 0 0 0
Inventories 46 18 10 6 0
Other Current Assets 11 4 8 6 6
Total Current Assets 339 375 246 450 297
Net Property & Equipment 17 22 25 18 15
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 10 104 202 218 0
Deposits & Other Assets 59 42 14 5 2
Total Assets 478 582 531 720 340
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 14 5 11 13 8
Current Portion Long-Term Debt 3 0 0 0 0
Current Portion Capital Leases 3 1 0 0 0
Accrued Expenses 54 59 40 33 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 11 7 12 11 11
Total Current Liabilities 89 76 67 61 41
Mortgages 0 0 0 0 0
Deferred Taxes/Income 70 79 74 77 48
Convertible Debt 427 379 281 181 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 1 1 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 630 569 463 346 115
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,927 1,767 1,466 1,501 1,070
Retained Earnings -2,078 -1,754 -1,398 -1,126 -844
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -152 13 68 374 225
Total Liabilities & Shareholder's Equity 478 582 531 720 340
Total Common Equity -152 13 68 374 225
Shares Outstanding 87.80 82.20 71.80 66.50 45.10
Book Value Per Share -1.73 0.15 0.95 5.63 5.00

Fiscal Year End for Revance Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 254 301 320 274
Receivables NA 28 25 17 15
Notes Receivable NA 0 0 0 0
Inventories NA 46 46 34 28
Other Current Assets NA 11 16 7 6
Total Current Assets NA 339 389 379 323
Net Property & Equipment NA 17 17 13 14
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 10 11 106 108
Deposits & Other Assets NA 59 61 66 65
Total Assets NA 478 532 598 548
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 14 5 8 13
Current Portion Long-Term Debt NA 3 10 0 0
Current Portion Capital Leases NA 3 0 16 19
Accrued Expenses NA 54 53 40 36
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 11 5 5 6
Total Current Liabilities NA 89 82 74 78
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 70 84 82 81
Convertible Debt NA 427 427 380 380
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 3 3 3
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 630 639 571 574
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,927 1,916 1,908 1,788
Retained Earnings NA -2,078 -2,023 -1,881 -1,814
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -152 -106 27 -27
Total Liabilities & Shareholder's Equity NA 478 532 598 548
Total Common Equity 0 -152 -106 27 -27
Shares Outstanding 104.20 87.80 87.90 84.00 84.00
Book Value Per Share 0.00 -1.73 -1.21 0.32 -0.32